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Abstract
Twenty  four  patients  with  lung  metastases  underwent  radiosurgery  treatment  between  October  2010  and  December  2012. 
Stereotactic conformal high-dose radiation therapy with Active Breathing Control (ABC) was conducted using the volumetric modulated 
arc therapy (VMAT) technique.
The median overall follow-up was 18 months (range 6-24 months), overall survival was 75%, and local control rate was 92%. 
The median time to progression was 4 months (range 1-18 months).There have been no cases of leucopenia, radiation esophagitis, 
mediastinitis or severe acute radiation pneumonitis. The late radiation effects Grade 2, according to the LENT SOMA scales, was 
observed in one patient (4%). The results of this study indicate that the usage of the stereotactic high-dose radiation therapy with ABC 
is safe and effective in the treatment of lung metastases.
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Introduction
The lungs are one of the most common sites for metastatic 
(secondary) lesions due to the presence of an extensive capillary 
network. Also, the lungs are the first organs, through which the 
venous blood passes after flowing into the vein of the greatest 
lymphatic  vessels.  Usually,  the  frequency  and  nature  of  the 
metastatic disease depend upon the localization of the primary 
tumor. In 6-30% cases it is the insulated metastatic lesions that 
get affected [1]. In about one-third of patients with insulated lung 
lesions, isolated pulmonary metastases are observed, which are 
located in the lung periphery [2] and are amenable to surgical 
or  combined  modality  treatments.  The  current  approaches  of 
the treatment include both radiation therapy and radiosurgery, 
which enable us to achieve not only a partial response, but also 
a  prolonged  remission  [3].  Thus,  metastatic  dissemination  in 
the lungs does not imply incurability in the cancer patients. The 
peripheral pulmonary tissue, according to radiobiological models, 
is a parallel structure. High radiation doses can be delivered to 
the metastases without any excessive risk of lung pulmonitis, 
assuming only a small volume of lung is subjected to irradiation.
Hyperfractionated radiation therapy is a procedure that has 
been clinically tested in escalation dose studies [4-6]. Patients with 
inoperable non-small cell lung cancer (NSCLC), T1 stage, were 
included in these studies. Researchers from Colorado University 
report that the maximal tolerable dose can be safely escalated 
from 48 to 60 Gy, delivered in 3 fractions [5]. In phase II of the 
study, 60 Gy was the dose given [5]. This dose enabled obtaining 
100% and 96% of actuarial local control at one and two years, 
respectively. Similar results were achieved in other studies by 
giving high-dose radiation to patients with NSCLC, T1 stage 
[4,6]. The response was observed to be dose-dependent and the 
local control rates improved with increasing doses of radiation. 
The objective of  this  study  was  the  estimation  of  the 
efficiency and tolerability of the high-dose stereotactic radiation 
therapy using the ABC in patients with isolated pulmonary lung 
metastasis.
Material and Methods
Twenty four patients (15 men and 9 women) with isolated 
pulmonary metastasis in the lung underwent hypofractionated 
stereotactic conformal radiation therapy. The mean age was 65.5 
years (range 52-79 years). Patients were treated in the Center 
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of Radiosurgery and Radiotherapy of the Meshalkin Research 
Institute  of  Circulation  Pathology  (Novosibirsk,  Russia) 
between October 2010 and December 2012. The characteristics, 
morphology and primary tumor sites of metastases of the patients 
are summarized in Table 1.
Inclusion criteria included age older than 18 years, patients 
with isolated pulmonary metastases in the lung periphery from 
any  primary  site,  except  leukemia  and  lymphoma,  maximum 
diameter  of  metastases  less  than  70  mm;  no  prior  radiation 
therapy in the past, sufficient lung performance (sustained arterial 
oxygen saturation more than 90% with minimal exercise stress, 
forced expiration volume in one second (FEV1) greater than 40% 
of the expected value, diffusing lung capacity more than 40% 
of the expected value); the absence of systemic therapy for two 
weeks  prior  and  post  irradiation, permitting the  small tumors 
outside the lungs; Karnofsky performance status (KRS) greater 
or equal to 70%.
The  exclusion  criteria  were  disease  progression, 
bleeding  threat,  evident  radioreaction  (hyperthermia,  acute 
agranulocytosis), lack of set-up reproducibility due to insufficient 
ABC tolerance, and other contradictions to radiation treatments.
Tumor response was estimated on contrasted-CT images 
through 3, 6, 12, 18, and 24 months post treatment or otherwise if 
indicated. The local control rate was independently assessed from 
a distant progression through six months. This type of follow-up 
period was chosen to exclude the early side effects and metabolic 
changes in the irradiated tissue [7,8]. 
All the patients were positioned supine on the table, with 
their  arms  above  their  heads.  The  ABC  device  was  used  to 
immobilize the lung during the CT session and treatment. Contrast 
(OmnipaqueTM) scans were acquired employing the Aquilion LB 
CT  scanner  (Toshiba  Medical  Systems,  Tokyo,  Japan),  using 
2 mm slice thickness. The CT images were transferred to the 
FocalPro station (Elekta Instruments AB) for targets and organs 
at  risk  (OAR)  delineation.  Dose  planning  was  done  utilizing 
ERGO++ treatment planning system (TPS) (Elekta Instruments 
AB). The target volumes were defined according to ICRU 50 [9]. 
The gross tumor volume (GTV) was the visible tumor. The clinical 
target volume (CTV) was generated to account for microscopic 
invasion by 10 mm expansion of the GTV. The planning target 
volume (PTV) was generated to account for set-up inaccuracy 
and organ motion by 5 mm for the upper and middle lobes and 
7 mm for the lower lobe of the lung expansion of the CTV. The 
treatment technique involved volumetric modulated arc therapy 
(VMAT).  Prior  to  each  treatment,  all  the  patients  received 
CBCT scans with ABC [10]. The tumor and critical positioning 
of structures were analyzed with Elekta X-ray volume imaging 
(XVI) software. Automated 3D registration of the reference CT 
planning scan and the XVI scans was performed using the cross-
correlation algorithm [11] provided in the Elekta XVI software.
The tumors were treated with a dose of 45-60 Gy, whilst 
the fraction dose was 15-20 Gy. The volume of the tumors and 
localization of the critical organs defined the fraction and overall 
doses. Radiation exposure to the critical organs (mediastinum, 
spinal cord, oesophagus, other lung, and liver) was estimated 
considering the tolerance levels of the normal adjacent tissues. 
The irradiation sessions were arranged every other day, and in 
exceptional cases every 3-5 days.
Results 
Tumor response estimations, post radiation treatment, were 
met with for 23 patients. No monitoring of the CT scans for the 
others was done; however, their treatment outcomes were decided 
on X-ray image evaluations and overall survival.
Tumor  regression  (complete,  partial,  stable  disease) 
based on CT image evaluation was 92%. Tumor parameters and 
irradiation doses are presented in Table 2.
The  median  overall  follow-up  was  18  months  (range 
6-24 months). The overall survival was 75% (18 patients) and 
the local control rate was 92%. The median time to progression 
Table 1.
Patients’ characteristics, morphology and the primary tumor sites of 
metastases
Patients’ characteristics Patients (n = 24)
Men 15 (62.5 %)
Women 9 (37.5 %)
Average age, yrs 65.5 
Co-morbidity 98%
Performance
ECOG WHO 1— 8 %, 2— 36 %, 3— 56 %
Smoking
Not once 5 (20.8 %)
Former smokers 14 (58.4 %)
Current smokers 5 (20.8 %)
Morphology
Squamous cell cancer 5 (20.8 %)
adenocarcinoma 18  (75 %)
—high-grade  2
— moderate-grade  9
— low-grade 6
— poorly 1
Clear cell carcinoma 1 (4.2 %)
Colon cancer 6 (27.7 %)
Breast cancer 8 (33.3 %)
Lung cancer 6 (22.2 %)
Ovary cancer 3 (11.1 %)
Endometrial stromal sarcoma 1 (5.5 %)
Table 2.
Tumor characteristics and fraction schemes
Characteristics %
Tumor
Peripheral 19 (90 %)
Central 5 (10 %)
An average diameter 36 ± 11mm
Volume 15.1 см3 (4.8–78 sm3)
Delivered dose (BED)
48 Gy/3 fr (105.6 Gy) 4(16.6 %)
54 Gy/3 fr (151.2 Gy) 14 (58.3 %)
60 Gy/3 fr (150 Gy) 2 (11.1 %)
20 Gy/1 fr (60 Gy) 4 (22.2 %)
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was four months (range 1-18 months) from the beginning of the 
radiosurgery. Figure 1 represents the CT images of the typical 
patients before and after irradiation.
Discussion
The first signs of progression were the distant metastases 
in  5  patients  and  the  local  recurrence  in  2  patients. With  23 
patients  enrolled  in  this  CT  image  evaluation,  the  complete 
response was 13% (3 patients), with 39.1% (9 patients) achieving 
a complete response, stable disease was found in 17.4% cases 
(4 patients) and 30.5% (7 patients) revealed progression of the 
disease. Five patients died by the end of the follow-up period, 
progression disease being the cause of death in three patients 
(local recurrence occurred in one patient, one case had several 
liver  metastases  found  on  CT  images  eight  months  after 
irradiation and one patient had metastases in the central nervous 
system (CNS)). One patient died due to a repeated heart attack 
through six months after irradiation, one patient had a spreading 
colon cancer. In one case, a patient with advanced breast cancer 
had stable disease over metastatic lung disease more than 12 
months  after  irradiation,  although  radiosurgery  of  the  CNS 
metastases was required. It should be noted, that no incidence 
of grade 3 or higher acute toxicity (RTOG scale) associated with 
irradiation were encountered in any of our patients. There have 
been no cases of leucopenia, radiation esophagitis, mediastinitis 
or severe acute radiation pneumonitis. The late radiation effects 
Grade 2, according to the LENT SOMA scales, was observed 
in one patient. This proves that radiosurgery for lung metastases 
provides excellent local control rates, rivaling those found in the 
studies of surgical management (the usual treatment of choice) 
for lung metastases [12]. Therefore, radiosurgery treatment may 
be the real alternative to tumor resection in patients with small 
lung metastases. The typical requirements for hyperfractionated 
radiation therapy include the largest diameter and the volume of 
the lesion not exceeding 70 mm and volume 15 cm3, respectively.
Conclusion
The  results  of  this  study  indicate  that  the  usage  of  the 
stereotactic high-dose radiation therapy with ABC is safe and 
effective in the treatment of lung metastases. Further studies are 
suggested to define the optimal dose and evaluate the advantages 
and disadvantages of the various treatment schedules. 
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Figure 1. 
The typical patient (age 57 years) with the isolated metastasis in the 
upper lobe of the left lung. Breast cancer, T2N1M1. Patient underwent 
high-dose radiation therapy: 54 Gy/3 fr. a) before treatment, b) 7 months 
after treatment. The complete response of the lesion can be seen.